Valuation : Roche Holding AG

Market Cap 287B 355B 306B 262B 493B 33,901B 494B 3,400B 1,327B 17,113B 1,332B 1,303B 56,744B P/E 2026 *
20x
P/E 2027 * 17.7x
Enterprise Value 297B 368B 317B 272B 512B 35,186B 513B 3,529B 1,377B 17,762B 1,382B 1,352B 58,895B EV / Sales 2026 *
4.75x
EV / Sales 2027 * 4.44x
Free-Float
88.78%
Yield 2026 *
2.79%
Yield 2027 * 2.85%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 355B
-1.82%-7.13%+57.51%+108.95% 1,047B
-0.61%-2.29%+49.83%+65.01% 646B
-0.05%-3.14%+20.90%+74.34% 451B
-1.77%-4.78%+35.55%+35.50% 355B
-0.57%-2.92%+21.19%+37.79% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.51%-2.98%+50.08%+67.98% 234B
-1.23%-2.31%-19.93%-54.11% 203B
-0.84%-1.75%+27.91%+88.51% 181B
Average -1.02%-2.68%+27.17%+48.39% 406.59B
Weighted average by Cap. -1.13%-3.46%+36.54%+64.77%

Financials

2026 *2027 *
Net sales 62.64B 77.54B 66.81B 57.19B 108B 7,411B 108B 743B 290B 3,741B 291B 285B 12,404B 65.47B 81.04B 69.83B 59.77B 113B 7,745B 113B 777B 303B 3,910B 304B 298B 12,964B
Net income 14.51B 17.95B 15.47B 13.24B 24.95B 1,716B 25.03B 172B 67.15B 866B 67.41B 65.94B 2,872B 16.33B 20.22B 17.42B 14.91B 28.09B 1,932B 28.18B 194B 75.6B 975B 75.9B 74.25B 3,234B
Net Debt 10.87B 13.45B 11.59B 9.92B 18.69B 1,285B 18.75B 129B 50.3B 649B 50.5B 49.4B 2,152B 4.02B 4.98B 4.29B 3.67B 6.91B 475B 6.93B 47.69B 18.61B 240B 18.68B 18.27B 796B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA